Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
ESG performance is eye-catching, and Health Yuan's MSCI rating has jumped to AA.
Published Time：
2023-10-31
Recently, MSCI, a leading international index agency, announced the results of its 2023 ESG (Environmental, Social, and Governance) rating for HealthGen, upgrading it from "BBB" to "AA" level. HealthGen's ESG rating was upgraded from "BBB" to "AA", representing an industry-leading level. This upgrade reflects international capital markets' recognition of HealthGen's ESG management achievements and its long-term sustainable development capabilities.
MSCI is one of the world's most authoritative ESG rating agencies. Its ratings are highly trusted by international capital markets and have become a key reference for mainstream investment. The MSCI-ESG rating scale includes industry leaders (AAA, AA), industry average (A, BBB, BB), and laggards (B, CCC). HealthGen's upgrade from industry average to industry leader reflects its outstanding performance in environmental protection, social contribution, and corporate governance.
As a leading innovative pharmaceutical company in China, HealthGen has continuously increased its R&D investment in recent years, focusing on innovative drugs and complex formulations with high technical difficulty. According to HealthGen's recently released third-quarter report, its R&D expenditure in the first three quarters of this year exceeded 1 billion yuan, reaching 1.212 billion yuan.
HealthGen recognizes that innovative R&D is fundamental to the company's survival and development, and is key to achieving sustainable growth. Over the years, HealthGen has continuously strengthened its R&D capabilities, focusing on key medical areas such as respiratory system, digestive system, mental health, assisted reproductive technology, and anti-cancer, and firmly implementing a dual-driven development strategy of "innovative drugs + high-barrier complex formulations". According to data released in the first half of 2023, HealthGen currently has 50 high-barrier complex formulation projects under development, including 2 projects that have received official approval, 6 projects that are submitting production license applications, 9 projects in clinical trials or bioequivalence studies, and 1 project that has been approved for clinical trials.
In terms of collaborative R&D, HealthGen's collaborative project TG-1000 with Taijing has successfully completed Phase II clinical trials and has initiated Phase III clinical trials. Thanks to continuous innovation and the application of complex formulation technology, HealthGen has developed into a pharmaceutical group with research and innovation as its core, a rich product line, and diversified R&D projects. Its business covers multiple medical areas with urgent clinical needs, including respiratory, digestive, assisted reproductive, psychoneurology, oncology, anti-infection, and metabolic diseases, demonstrating industry competitiveness and social value.
The R&D achievements in multiple fields have laid a solid foundation for HealthGen to give back to society. HealthGen always remembers its important responsibilities as a "corporate citizen." Leveraging its strength in the pharmaceutical and healthcare industry, HealthGen, together with its subsidiary Lizhu Group, actively responds to the national call and participates in various social welfare activities. The company vigorously promotes the "Universal Chronic Disease Prevention and Control Public Welfare Project," donating chronic disease medications to bring tangible health benefits to local residents. As of June 2023, this public welfare project has benefited 8 provinces and 2 autonomous regions across China, including 19 remote areas in need of assistance and 2 national-level nature reserves, providing assistance to over 17,700 low-income residents. This project has consecutively won the "ESG Excellent Practice Model Award" and "2022 China Pharmaceutical Social Responsibility Media Observation Responsibility Pioneer" in 2022 and 2023, affirming HealthGen's outstanding contributions in social responsibility practice.
In the future, HealthGen will continue to strengthen corporate governance, continuously promote the construction of the ESG system, fulfill its responsibilities in economic, social, and environmental aspects, and practice sustainable development strategies during its operation and business development. In social welfare projects, HealthGen plans to expand its drug donation coverage to more remote areas in urgent need of assistance, ensuring that medicines can truly benefit low-income people at the grassroots level, driving the company's sustainable development through innovation and social responsibility.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.